Search from website
Search from website
From antibody humanization and reformatting to afucosylated bispecific antibodies – we have developed and produced them all. Our technology and experience gives us an ability to discover antibodies against difficult multi-pass transmembrane proteins.
Icosagen provides antibody discovery and development services, using proprietary technologies.
We engineer diverse modalities of bispecific and multispecific antibodies, seamlessly integrating knowledge with practical expertise in structural and computational biology, bioinformatics in engineering, and production with tailored purification strategies.
Our rich expertise in engineering and format design, enables us to assess the feasibility of different combinations and designs, distinguishing between those with potential and those that may pose limitations.
To optimize therapeutic potential of a selected lead candidate, we can enhance or decrease its affinity, improve binding specificity to prevent off-target effects, mitigate aggregation and reduce immunogenicity through humanization. Further, we can modulate its half-life, immune cell binding and activation, and meticulously examine each molecule using tailored in vitro and in vivo assays.
One-stop-shop for bispecifics.
From antigen design and production to immunization, followed by discovery, engineering, optimization, production, and purification, we always deliver!
We can rationally assess different antibody projects to find right strategies towards generation of high affinity antibodies.
Our proprietary platform has undergone thorough testing and analysis, and when coupled with expert manual execution, has demonstrated outstanding effectiveness in enhancing antibody affinity and specificity.
Affinity maturation can be combined with antibody humanization.
Humanization of antibodies discovered from non-humanized animals or libraries is a necessity for their use as therapeutics. The challenge is to retain the desired specificity and affinity, while engineering away their immunogenic properties.
Our humanization platform service benefits from a proprietary software developed in collaboration with the University of Tartu.
We routinely humanize variable regions and framework sequences from any species, using any reference sequence as the basis. Key residues important for the VH/VL interface and antibody structure are maintained as much as possible in the humanized variants. Humanized sequences are screened to be free of motifs that are prone to glycosylation, deamidation or other PTMS.